Sec. 5. Prohibition on Certain Uses of Data Obtained from Comparative Effectiveness Research; Accounting for Personalized Medicine and Differences in Patient Treatment Response

175 words·~1 min read·/bill/113/s/2064/is/section-5

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Notwithstanding any other provision of law, the Secretary of Health and Human Services— shall not use data obtained from the conduct of comparative effectiveness research, including such research that is conducted or supported using funds appropriated under the American Recovery and Reinvestment Act of 2009 ( Public Law 111–5 ) or authorized or appropriated under the Patient Protection and Affordable Care Act ( Public Law 111–148 ), to deny or delay coverage of an item or service under a Federal health care program (as defined in section 1128B(f) of the Social Security Act (42 U.S.C. 1320a–7b(f))); and shall ensure that comparative effectiveness research conducted or supported by the Federal Government accounts for factors contributing to differences in the treatment response and treatment preferences of patients, including patient-reported outcomes, genomics and personalized medicine, the unique needs of health disparity populations, and indirect patient benefits.

Nothing in this section shall be construed as affecting the authority of the Commissioner of Food and Drugs under the Federal Food, Drug, and Cosmetic Act or the Public Health Service Act.

Connections3 off-index

3 references not yet in our index

Pub. L. 111-5
Pub. L. 111-148
42 USC 1320a–7b(f)

Citation graph

cites case law

Sec. 5

Prohibition on Certain Uses of Data Obtained from Comparative Effectiveness Research; Accounting for Personalized Medicine and Differences in Patient Treatment Response

Pub. L.Pub. L. 111-5

Pub. L.Pub. L. 111-148

Cite42 USC 1320a–7b(f)

Cites 3Cited by 0 across 0 sources